AstraZeneca, Novo Nordisk shares: anti-obesity drugs to lift companies that fill ‘skinny pens’
Global syringe-filling facilities are struggling to cope with rising demand for anti-obesity drugs, which require injection pens.
Which companies are likely to benefit from ‘fill-finish’ demand in the near-term? IGTV financial analyst Angeline Ong investigates.
(AI Video Summary)
Injection weight loss drugs market on the rise
The market for weight loss drugs that can be injected by oneself is growing rapidly. In fact, experts predict that this market could be worth an incredible $100 billion in the next ten years. Many big companies like Novo Nordisk, Eli Lilly & Co, AstraZeneca, Amgen, and Pfizer are all competing to provide these drugs.
One popular drug called Wegovy, created by Novo Nordisk, has been a hit since it was launched in the US in June 2021. It works by mimicking the appetite-suppressing hormones in the body. The interesting thing is that even though experts have warned about unknown risks and the high price of over $1,000 for a month's supply, people are still clamoring for these drugs. This high demand has even made it difficult for people with diabetes, who also need similar medications, to get the treatment they need.
Investing in "skinny pen" manufacturers
Now, here's where the investment opportunity comes in. Instead of investing in the companies that make the drugs themselves, you can consider investing in the companies that manufacture the injection pens used for these weight loss drugs. These portable devices, known as "skinny pens," are essential for administering the medication. The major drug manufacturers are struggling to keep up with the demand for these pens, as it requires a specialized process to fill them with the medication in sterile conditions.
That's where companies like Catalent and Thermo Fisher Scientific come in. They specialise in the process of filling these pens, which is called fill finish work. They can step in and bridge the gap in capacity until the big drug makers can establish their own facilities for fill finish work.
Investing in these companies that provide fill finish services could be a less risky option for those interested in the booming weight loss drug market. By putting your money into these companies, you are tapping into a crucial part of the supply chain and taking advantage of the growing demand for self-injection weight loss drugs.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Act on share opportunities today
Go long or short on thousands of international stocks with spread bets and CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
